Androgen Deprivation Therapy (ADT) and Pembrolizumab for Advanced Stage Androgen Receptor-positive Salivary Gland Carcinoma

Part of paid clinical trials in Chicago, Illinois.

Sponsor
Manish Patel
Study ID
NCT03942653
Phase
PHASE2
Status
Active Not Recruiting

Conditions

  • Salivary Gland Carcinoma

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Goserelin Acetate — DRUG
    Goserelin Acetate, SQ, Q4W
  • Pembrolizumab — DRUG
    Pembrolizumab, IV, Q3W

Study Details

A Phase II, multi-center, single-arm, non-blinded study combining androgen deprivation therapy (ADT) and pembrolizumab for patients with metastatic or locally recurrent androgen receptor-positive salivary gland carcinoma, not amenable to surgery or radiation.

Key Dates

First listed
May 8, 2019
Start date
May 30, 2019
Status verified
Jul 2026
Primary completion
Jul 31, 2026
Completion
Aug 31, 2026

Study Design

Enrollment
20 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Goserelin Acetate + Pembrolizumab
    Goserelin Acetate, 3.6 mg, every four weeks, SQ Pembrolizumab, 200mg, every three weeks, IV

Primary Outcome Measure

Objective Response Rate [ Time Frame: 35 months ]

Locations (7)

FacilityCityStateZIPSite coordinators
Northwestern University Feinberg School of MedicineChicagoIllinois60611-
University of Illinois Cancer CenterChicagoIllinois60612-
University of Iowa Hospitals and ClinicsIowa CityIowa52242-
Univeristy of MarylandBaltimoreMaryland21201-
University of Michigan Health SystemAnn ArborMichigan48109-
University of Minnesota: Masonic Cancer CenterMinneapolisMinnesota55455-
University of WisconsinMadisonWisconsin53705-

Find similar trials in Chicago, IL

By research site
Northwestern University Feinberg School of Medicine· Chicago, ILUniversity of Illinois Cancer Center· Chicago, ILUniversity of Iowa Hospitals and Clinics· Iowa City, IAUniveristy of Maryland· Baltimore, MDUniversity of Michigan Health System· Ann Arbor, MIUniversity of Minnesota: Masonic Cancer Center· Minneapolis, MN